Violation Tracker Individual Record

Company: 
Mylan Laboratories et al.
Current Parent Company: 
Mylan
Penalty: 
$108,000,000
Year: 
2000
Date: 
November 29, 2000
Offense Group: 
competition-related offenses
Primary Offense: 
price-fixing or anti-competitive practices
Violation Description: 

Mylan paid $100 million (plus $8 million in legal fees) to settle a price-fixing case alleging that it developed a plan to drastically increase prices on two of its generic drugs by cutting off its competitors' supply of the drugs' active ingredients. Mylan accomplished this by entering into long-term profit-sharing agreements with industry suppliers and distributors that gave Mylan the only reliable sources of the active ingredients. The three other defendants -- which apparently were not required to share in the settlement costs -- were New Jersey-based Cambrex Corporation, Italian pharmaceutical ingredient manufacturer Profarmaco S.r.l. (a subsidiary of Cambrex), and New York-based drug distributor Gyma. The settlement was also announced by the Federal Trade Commission (see separate entry).

Level of Government: 
state
Action Type: 
agency action
Agency: 
Multistate Attorneys General Case
Court: 
District of the District of Columbia
Civil or Criminal Case: 
civil
Case ID: 
1:98-cv-3115
Case Name: 
Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation)
HQ Country of Parent: 
Netherlands (reincorporated for tax reasons)
Ownership Structure of Parent: 
publicly traded
Major Industry of Parent: 
pharmaceuticals
Specific Industry of Parent: 
pharmaceuticals
Link to PACER Case Docket (must be logged in): 
Link to Archived Court Document: 
Source Notes: 
If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Parent company note: 
Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.